Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amylin timeline

Amylin timeline

DateEventApr 1994AMLN and Glaxo agree to study compounds that block amylinJun 1994Presents data from Phase II studies showing amylin (AC137, pramlintide) improves glucose control in Type I diabetesAug 1994Chairman and CEO Ted Greene and five directors invest in a $6.8M private placement at $6.50Jun 1995 GlaxoWellcome ends partnership following the merger of

Read the full 541 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers